Loading in 2 Seconds...
Loading in 2 Seconds...
Towards adequate and non-discriminative HCV policies and services for drug users in Central and Eastern Europe. Simona Merkinaite, Central and Eastern European Harm Reduction Network 18th International Conference on the Reduction of Drug Related Harm, May 13 – 17, 2007, Poland.
Simona Merkinaite, Central and Eastern European Harm Reduction Network
18th International Conference on the Reduction of Drug Related Harm, May 13 – 17, 2007, Poland
Overall data is limited
- the Czech Republic, Hungary, Romania, Slovenia and Slovakia;
- Bulgaria (79%), Poland (68.3%) and Romania (84.45);
ACP – anonymous consultation points; DTC – drug treatment centers; LTF – low threshold facilities, NSP – needle/syringe exchange points, OST – opioid substitution treatment programs
- Only 2 out of 13 countries (Romania and Slovakia) have specific national plan or strategy addressing hepatitis;
- Declaration on hepatitis C adopted by European Parliament in March 2007. Lack of EU strategy identified as one of negative factors affecting lack of national action by activists in countries);
Such estimates never done for Eastern part of Europe
Testing at needle exchange or substitution treatment programs available in 5 out of 13 countries
In some countries testing available at entrance to drug treatment (Czech Republic, Lithuania, Slovakia, Slovenia) and as part of HIV diagnostics
- in pharmacies available in 4 out of 13 countries
International guidelines clearly state that active drug use should not be an exclusionary criterion… any assessment of treatment eligibility should be made on case-by-case basis
- Bulgaria, Czech Republic, Estonia, Hungary, Lithuania, Slovakia;
- Hungary - from 6 to 12 months;
- Slovakia – requirement by health insurance companies;
- Estonia - 80%; Latvia - 61%; Russia - 52%; and Ukraine - 77–80%).
(WHO Europe, 2006)
- In Belarus 40-50 people with HIV will receive HCV treatment in the framework of Global Fund grant
- Ukraine – with the support of World Bank plans to enroll 200 people living with HIV in HCV treatment. As of Feb, 2007 the drugs still were not purchased)
WHO (2005). Status Paper on Prisons, Drugs and Harm Reduction, World Health Organization Regional Office for Europe, Copenhagen, 2005.
- currently no needle and syringe programs;
- substitution treatment only in the Czech Republic, Poland, Slovenia.
- In Slovakia suggested to all suspected, diagnosed, self-reported drug users
- In the Czech R. mandatory to all suspected, self-reported drug users;
needle and syringe exchange and provision of other injecting equipment; drug treatment, including substitution treatment; education and counseling, low threshold, voluntary testing with pre- and post-test counseling for HCV; peer education and support; vaccination for hepatitis A and B
Other CEEHRN publications on HCV